18 results about "Viral antigens" patented technology

The present invention relates to a recombinant vaccine comprising a PIV5-based viral expression vector with a genetic insert, and methods of producing and using the same. The recombinant vaccine comprises a modified bacterial or viral antigen to increase expression of the antigen on the surface of cells (AOS) to increase immunogenicity to the antigen.

This invention involves, among other things, elements that stimulate an immune response. Which includes: a) one or more antigens of Avibacterium paragallinarum and One or more antigens of avian brain and spinal cord rhizomatous virus and one antigen. or more of avian porcine ... Furthermore, this invention relates to a method for immunizing animals which includes administration. The animal drug contains components that stimulate the immune response of this invention; moreover, This invention relates to a method of treating or preventing clinical signs caused by Avibactericum. Paragallinarum, a viral infection that causes encephalitis and spinal cord inflammation in birds and avian pox virus in animals. Essential, a method that involves administering medication to animals in effective dosages as a form of treatment. The components that stimulate an immune response are consistent with this invention;

The present invention relates to a nucleic acid molecule encoding a multispecific antigen-binding protein and exhibiting significantly improved expression efficiency in vivo. In the multispecific antigen-binding protein of the present invention, specifically, a bispecific antibody that recognizes a tumor antigen or a viral antigen and a natural killer cell-specific activating receptor, the light chain variable region (VL) and the heavy chain variable region (VH) of a receptor-recognizing site of a natural killer cell-specific activating receptor are sequentially arranged in the N-terminus to the C-terminus direction, thereby increasing expression efficiency by up to 8-fold. Therefore, the present invention provides an optimal mRNA structure capable of most efficiently expressing bispecific antibodies in vitro and in vivo, thereby enabling effective use thereof for not only mass-production of recombinant bispecific antibodies but also as an excellent mRNA therapeutic agent for stable and continuous production of a therapeutically effective amount of bispecific antibodies in the body of a patient.

Immunogenic compositions and methods of use thereof, for eliciting an immune response against one or more virally driven cancers are described. The compositions typically include one or more viral antigens expressed in the virally driven cancers, or a nucleic acid encoding the same, and optionally one or more adjuvants. Preferably, the compositions include nucleic acids (e.g., mRNA) encoding one or more viral antigens. Exemplary antigens include those derived from a truncated form of the viral Large T Antigen (LTA) or Small T Antigen (STA) of Merkel Cell Polyomavirus (MCPyV), or E2, E5, or E6 proteins of HPV. Pharmaceutical compositions and dosages including one or more of the compositions and an excipient, and methods of immunizing subjects and priming and engineer T cells for use in adoptive therapy are also provided.

The utility model provides a kind of virus antigen rapid detection test paper, it is related to biological detection technical field, multi-dimensional gradient compound synergistic component, integrate dendritic flow guide groove and nano microporous structure on sample pad, it can promote processing liquid and sample to be radially evenly distributed in diffusion process, on the one hand, effectively avoid the detection interference caused by local liquid concentration too high, on the other hand, significantly shorten the liquid infiltration time of detection starting stage, improve chromatography efficiency, set up gradient distribution's antigen line on NC membrane, its virus specificity antigen concentration is increasing distribution from the end close to binding pad to bibulous pad, accurately adapt the detection requirement of different virus load sample, low virus load sample because of less combined compound, can flow to bibulous pad end high concentration antigen area sufficient combination and produce strong signal, avoid missed detection, high virus load sample because of compound sufficiency, preferentially and binding pad end low concentration antigen area quickly combine, effectively avoid signal inhibition or false negative problem.

The application discloses a method for inducing Breg cell proliferation in vitro. The method comprises the following steps: (1) culturing B cells derived from mammals in a culture medium containing CD40 antibodies; (2) adding SARS-CoV-2 virus antigens to the culture system, wherein the SARS-CoV-2 virus antigens are selected from one or more of N protein, S protein specific epitope peptide segments or S1 subunits containing RBD regions of S protein; and (3) after 24-96 hours of culture, the induction of Breg cells is achieved. The application uses SARS-CoV-2 specific protein antigens to significantly improve the proportion of B cell conversion to Breg cells, and realizes the specific induction of Breg (CD19 + IL-10 + ) cell proliferation and differentiation under in vitro conditions.

This application discloses a chimeric antigen comprising dengue virus NS5 antigen and E antigen. Specifically, this application relates to a chimeric antigen, a nucleic acid molecule, an expression vector, a host cell, reagents, a kit, and its uses. The chimeric antigen of this application, or its conjugates, possesses enhanced activity and can be used to prepare kits for accurate detection of antibodies against dengue virus.

The application provides a kind of construction and application of multi-stage targeted carrier of viral antigen and adjuvant.It is a kind of nanometer loading SARS-CoV-2 and other viral recombinant protein antigens and vaccine adjuvant Toll-like receptor agonists by using liposome, solid lipid nanoparticle, nanoemulsion, polymer micelle and nanocapsule, etc., the surface of the nanocarrier is modified by using mannose and cationic peptide Par, and the nanocarrier is endowed with multi-stage targeting of dendritic cells and endoplasmic reticulum.By adjusting the ratio of Man and Par, the processing of SARS-CoV-2 and other viral recombinant protein antigens in the endoplasmic reticulum and lysosome of DC cells can be effectively regulated, the presentation of exogenous antigens by DC cells is enhanced, and the initiation of CD8+ and CD4+ T cells in the body is promoted; meanwhile, the nanocarrier can also deliver very low dose of CpG-OND adjuvant directly to the endoplasmic reticulum of DC cells to play a role, and the potential immunotoxicity induced by the adjuvant is reduced.

The present invention relates to recombinant Modified Vaccina Virus Ankara (MVA) encoding Epstein-Barr virus (EBV) antigens, wherein surface glycoprotein 350 (EBV gp350) and glycoprotein gH (EBV gH) are fused to subunits of self-assembling multimeric protein particle PdhC (acetyltransferase of pyruvate dehydrogenase (PDH) complex) or DPS (DNA binding protein from starved cells).

The application discloses a kind of digital signal amplification immunodetection method and system based on surface open magnetic bead array.The method is to construct open surface magnetic bead array on transparent flexible substrate using external magnetic field, while combining reciprocating flow microfluidic technology to accelerate antigen-antibody binding reaction, adopt tyramide signal amplification strategy to realize in situ fluorescence deposition, and combine deep learning-based image recognition algorithm to automatically identify positive magnetic beads, realize quantitative analysis.The method has a significant advantage of high sensitivity and rapid detection with a detection sensitivity of fg / mL order and a detection time of less than 20 minutes.The system includes a magnetic field generation module, a reciprocating flow driving module, an enzymatic signal amplification module, an optical acquisition module and an AI recognition module.It can be used for ultra-sensitive quantitative detection of various human proteins, inflammatory factors, viral antigens and other low-abundance biomarkers.

The application discloses a method for establishing a human alpha beta TCR and pMHC binding probability prediction model. The application designs a coding mode of TCR and pMHC amino acid sequences, trains a convolutional neural network through a machine learning method, and can predict the binding probability of TCR and pMHC. The prediction method has high prediction accuracy on unknown TCR, good generalization on single-chain TCR, double-chain TCR and single-double-chain mixed data, good prediction effect on CMV virus antigen-specific TCR, and is helpful for the research of T cell immunity.

This invention discloses a method for in vitro expansion and culture of TCR cells targeting viral antigens, belonging to the field of in vitro immune cell culture technology. The specific steps of this method are as follows: first, peripheral blood mononuclear cells are isolated, and the initial activation of targeted T cells is completed and a culture system is established to start expansion; samples are taken at preset nodes, and the abundance of targeted and non-targeted TCR clones is calculated by single-cell TCR sequencing; culture parameters are dynamically adjusted according to abundance thresholds, and targeted enrichment is performed when non-targeted clones exceed the limit; the operation is repeated until the end of the expansion cycle and the cells are harvested. This invention integrates targeted clone abundance detection into the culture process by using fixed-node micro-sampling sequencing throughout the expansion process, combined with three-level graded threshold dynamic control of culture parameters, and dual-detection abundance correction. When non-targeted clones exceed the limit, they are enriched in real time, locking in the proliferative advantage of targeted clones, reducing cell viability loss during sorting, minimizing batch quality differences, and stably producing high-purity targeted TCR cells that meet clinical requirements.

The present invention provides recombinant peptides comprising soluble respiratory syncytial virus (RSV) viral antigens comprising a recombinant F protein peptide joined via an in-frame fusion to a collagen C-terminal portion to form a disulfide-linked trimeric fusion protein, and immunogenic compositions comprising the same. The immunogenic compositions can be used to generate an immune response, e.g., for the treatment or prevention of RSV infection. The immunogenic compositions can be used in vaccine compositions, e.g., as part of a prophylactic and / or therapeutic vaccine.

Aspects of the disclosure relate to compositions and methods for modulating the immune response of a subject (e.g., a human subject) to certain viral antigens (e.g., antigens derived from AAV capsid proteins). The disclosure is based, in part, on isolated nucleic acids and expression constructs encoding chimeric antigen receptors (CARs) that target AAV capsid proteins, and recombinant immune cells comprising such constructs (e.g., recombinant T-cell comprising a CAR (CAR T-cells), and recombinant T-regulatory cells comprising a CAR (CAR T-regs)).

A nanobody-based point-of-care lateral flow immunoassay (LFA) for the rapid, cost-effective detection of SARS-CoV-2 and MERS-CoV proteins in biological samples is disclosed. The assay described herein uses nanobody-based binding agents that selectively capture and detect viral antigens, such as spike (S) proteins and receptor-binding domains (RBDs), with high sensitivity and specificity. The LFA utilizes a colorimetric readout visible to the naked eye, eliminating the need for specialized equipment. The assay supports single and multiplex detection formats, enabling simultaneous analysis of multiple viral analytes. The LFAs are stable under standard storage conditions and provide a practical solution for decentralized and scalable testing.

The present invention relates to a composition for detecting viruses comprising gold nanoparticles conjugated with a capture antibody or a detection antibody as an active ingredient. By confirming that a mixture of gold nanoparticles conjugated with a capture antibody and gold nanoparticles conjugated with a detection antibody effectively detects viral antigens and that a diagnostic kit prepared from said mixture is more effective in diagnosing viral infectious diseases than a conventionally used diagnostic kit, the composition can be usefully utilized as a virus detection composition or a diagnostic kit for viral infectious diseases.

This disclosure describes compounds that engage NK cells and methods of using the compounds. Generally, the compound includes an NK engaging domain, a targeting domain that selectively binds to a target cell, and an NK activating domain operably linking the NK engaging domain and the targeting domain. In an illustrative embodiment, the targeting domain selectively binds to an HIV antigen.

This utility model relates to the field of virus detection technology and discloses a multi-virus detection kit, including a first kit shell, a second kit shell, a third kit shell, and a fourth kit shell. The tops of the first and second kit shells are rotatably connected on opposite sides, and the bottoms of the first and third kit shells, and the second and fourth kit shells are rotatably connected on opposite sides. When it is necessary to detect multiple viral antigens simultaneously, this utility model unfolds the first, second, third, and fourth kit shells, allowing a first magnetic block to extend into the interior of a circular hole and attract with a second magnetic block. This allows the first, second, third, and fourth kit shells to be laid flat and simultaneously detect multiple viral antigens.